

IL6

Research Grade Ziltivekimab

Catalog No.	DHC15802A	Quantity:	100 µg
	DHC15802B		1.0 mg

Alternate Names: Interleukin-6, B-cell stimulatory factor 2, BSF-2, CTL differentiation factor, CDF, Hybridoma growth factor, Interferon beta-2, IFN-beta-2

Description: Ziltivekimab is a humanized monoclonal antibody directed against the IL-6 ligand. It was developed to inhibit pro-inflammatory IL-6 signaling in conditions that are associated with systemic inflammation, including atherosclerosis, chronic kidney disease, and rheumatoid arthritis, and it has also been explored for anti-tumor activity. The Fc domain of ziltivekimab has been engineered to extend its half-life by increasing affinity for FcRn.

UniProt ID (target): P05231

Specificity: Human IL-6

Source: XtenCHO cell line

Isotype: Humanized IgG1-kappa

INN: Ziltivekimab

Concentration: 1.0 mg/ml, lot specific

Formulation: 0.01M PBS, pH 7.4.

Purity: > 95% as determined by SDS-PAGE

Purification: Protein A/G affinity chromatography

Endotoxin: ≤ 0.01 EU/µg by LAL analysis

Storage & Stability: Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. **Avoid freeze/thaw cycles.**

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

